Physician profile
Chanel L Sinclair
NPI 1730614785
$2,833.24
in general payments reported to CMS, 2019-2025
27 companies · $666 in 2025
The $666 reported for 2025 was more than what 86% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $117 · 2021: $142 · 2022: $340 · 2023: $837 · 2024: $731 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $457.30 | 2022-2025 | |
| Abbvie INC. | $352.55 | 2020-2024 | Lo Loestrin Fe, Liletta, Orilissa |
| Optumhealth Care Solutions, LLC | $260.06 | 2023-2025 | Vivify Health Care Team Portal 001, Eitan Medical, Vivify Health Care Team Portal |
| Exact Sciences Corporation | $207.19 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $199.01 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $198.07 | 2023-2025 | Slynd |
| Biogen, INC. | $152.84 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $143.47 | 2021-2022 | |
| Organon LLC | $138.34 | 2022-2024 | Nexplanon, Jada System |
| Shield Therapeutics INC | $120.73 | 2023-2025 | Accrufer |
| Astellas Pharma US INC | $106.78 | 2024-2025 | Veozah |
| Coopersurgical, INC. | $85.55 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $69.45 | 2022-2025 | |
| Agile Therapeutics, INC. | $44.10 | 2023-2024 | Twirla |
| Hologic Sales and Service, LLC | $37.48 | 2021-2024 | Acessa Provu System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $35.56 | 2024-2025 | Intrarosa |
| Gynesonics, INC. | $33.70 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Pfizer INC. | $33.19 | 2024 | |
| Evofem Biosciences, INC. | $29.14 | 2022 | |
| Convatec INC. | $19.50 | 2022 | |
| Novo Nordisk INC | $19.42 | 2022 | |
| Minerva Surgical, INC | $16.92 | 2023 | |
| Medicem INC. | $16.26 | 2022 | |
| Aspira Women'S Health INC | $15.25 | 2024 | Ova1 |
| Therapeuticsmd, INC. | $14.70 | 2022 | |
| Amgen INC. | $13.35 | 2022 | |
| Avion Pharmaceuticals | $13.33 | 2023 | Balcoltra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chanel Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.